MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.7200
+0.0198
+2.83%
Opening 10:13 05/12 EDT
OPEN
0.6887
PREV CLOSE
0.7002
HIGH
0.7448
LOW
0.6887
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
3.179
52 WEEK LOW
0.3040
MARKET CAP
165.02M
P/E (TTM)
-1.4827
1D
5D
1M
3M
1Y
5Y
1D
Here are the major earnings after the close today
Seeking Alpha · 13m ago
Weekly Report: what happened at SGMO last week (0505-0509)?
Weekly Report · 4h ago
Earnings Scheduled For May 12, 2025
Benzinga · 5h ago
Sangamo Therapeutics Q1 2025 Earnings Preview
Seeking Alpha · 16h ago
Earnings week ahead: PLUG, CSCO, WMT, BABA, AMT, JD, TCEHY, and more
Seeking Alpha · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Iradimed (IRMD) and Sangamo Biosciences (SGMO)
TipRanks · 5d ago
Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Dow Jones · 5d ago
More
About SGMO
More
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Recently
Symbol
Price
%Change

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.